Trial of AMNIOECHANGE in Gastroschisis Affected Foetuses (AMNIOECHANGE)
Primary Purpose
Gastroschisis
Status
Unknown status
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
AMNIOECHANGE
Sponsored by
About this trial
This is an interventional treatment trial for Gastroschisis
Eligibility Criteria
Inclusion Criteria: Seen before 30 GA weeks Normal karyotype Single pregnancy Isolated gastroschisis No associated disease (maternal) Accept randomization and understand the study Exclusion Criteria: Maternal diabetes Maternal infection with HIV, hepatitis Preexistent oligohydramnios before inclusion
Sites / Locations
- Robert Debre hospital, AP-HP
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
No Intervention
Arm Label
AMNIOECHANGE
placebo
Arm Description
The AMNIOECHANGE consists of a transabdominal infusion of saline.They will be repeated every 15 days from 30 week of amenorrhea.
This will be done at the same place and under the same aseptic conditions a AMNIOECHANGE true.
Outcomes
Primary Outcome Measures
Duration of ventilation in the ICU and the duration of parenteral nutrition
The primary outcome was a composite endpoint based on the duration of ventilation in the ICU and the duration of parenteral nutrition
Secondary Outcome Measures
Evaluation of the contribution of iterative AMNIOECHANGE
Obstetric complications: chorioamnionitis, preterm labor, premature rupture of membranes,
Aspect périviscérite, age out of intensive care and the initialization of enteral nutrition, infection
Evaluation of complications of surgery, duration of hospitalization.
And to determine prenatal prognostic factors: 1. Ultrasound 2. Biological and postnatal: Histology
Full Information
NCT ID
NCT00127946
First Posted
August 8, 2005
Last Updated
August 8, 2011
Sponsor
Assistance Publique - Hôpitaux de Paris
1. Study Identification
Unique Protocol Identification Number
NCT00127946
Brief Title
Trial of AMNIOECHANGE in Gastroschisis Affected Foetuses
Acronym
AMNIOECHANGE
Official Title
Randomized Trial of AMNIOECHANGE in Gastroschisis Affected Foetuses
Study Type
Interventional
2. Study Status
Record Verification Date
August 2005
Overall Recruitment Status
Unknown status
Study Start Date
November 2005 (undefined)
Primary Completion Date
April 2012 (Anticipated)
Study Completion Date
April 2012 (Anticipated)
3. Sponsor/Collaborators
Name of the Sponsor
Assistance Publique - Hôpitaux de Paris
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Hypothesis: Gastroschisis is a localised disruption of the abdominal layer. It occurs early in gestation, and the bowel is therefore bathing in the amniotic fluid and can be constricted at the level of the abdominal hole. The bowel is therefore submitted to different injuries partly attributable to the contact with amniotic fluid contaminated by digestive compounds and inducing an inflammatory reaction. Experimental studies on animal models and preliminary data in humans indicate that changing regularly the amniotic fluid (i.e. AMNIOECHANGE) would improve the outcome of theses fetuses and then neonates.
Detailed Description
Primary Objective: To compare prospectively the effect of AMNIOECHANGE against classical care on the delay of full enteral feeding in gastroschisis affected foetuses
Study:
Multicenter, Randomized.
Inclusion at 20 GA (gestational age) weeks.
AMNIOECHANGE every 2 weeks from 30 GA weeks
Subject: 140 inclusion during 3 years
Analysis: Triangular Sequential Evaluation
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastroschisis
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
140 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
AMNIOECHANGE
Arm Type
Active Comparator
Arm Description
The AMNIOECHANGE consists of a transabdominal infusion of saline.They will be repeated every 15 days from 30 week of amenorrhea.
Arm Title
placebo
Arm Type
No Intervention
Arm Description
This will be done at the same place and under the same aseptic conditions a AMNIOECHANGE true.
Intervention Type
Procedure
Intervention Name(s)
AMNIOECHANGE
Intervention Description
The AMNIOECHANGE consists of a transabdominal infusion of saline (heated to 37 ° C) with a needle 18 or 20 gauge under ultrasound monitoring while avoiding the placenta. In the case of a normal amniotic fluid, it must be replaced volume per volume of saline (eg depending on the tank where the puncture is made, it can be 300 per 300 ml). The total amount of amniotic fluid exchange is 600-900 ml. In cases of oligohydramnios, the AMNIOECHANGE results in a normalized volume of amniotic fluid.
Primary Outcome Measure Information:
Title
Duration of ventilation in the ICU and the duration of parenteral nutrition
Description
The primary outcome was a composite endpoint based on the duration of ventilation in the ICU and the duration of parenteral nutrition
Time Frame
7 days and 45 days after the birth of the child
Secondary Outcome Measure Information:
Title
Evaluation of the contribution of iterative AMNIOECHANGE
Description
Obstetric complications: chorioamnionitis, preterm labor, premature rupture of membranes,
Aspect périviscérite, age out of intensive care and the initialization of enteral nutrition, infection
Evaluation of complications of surgery, duration of hospitalization.
And to determine prenatal prognostic factors: 1. Ultrasound 2. Biological and postnatal: Histology
Time Frame
7 days, 45 days, 12 months and 18 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Seen before 30 GA weeks
Normal karyotype
Single pregnancy
Isolated gastroschisis
No associated disease (maternal)
Accept randomization and understand the study
Exclusion Criteria:
Maternal diabetes
Maternal infection with HIV, hepatitis
Preexistent oligohydramnios before inclusion
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dominique Luton, MD, PhD
Organizational Affiliation
Assistance Publique - Hôpitaux de Paris
Official's Role
Study Chair
Facility Information:
Facility Name
Robert Debre hospital, AP-HP
City
Paris
ZIP/Postal Code
75019
Country
France
12. IPD Sharing Statement
Citations:
PubMed Identifier
31033140
Citation
Luton D, Mitanchez D, Winer N, Muller F, Gallot D, Perrotin F, Jouannic JM, Bretelle F, de Lagausie P, Ville Y, Guibourdenche J, Oury JF, Alberti C, Benachi A. A randomised controlled trial of amnioexchange for fetal gastroschisis. BJOG. 2019 Sep;126(10):1233-1241. doi: 10.1111/1471-0528.15804. Epub 2019 May 20.
Results Reference
derived
Learn more about this trial
Trial of AMNIOECHANGE in Gastroschisis Affected Foetuses
We'll reach out to this number within 24 hrs